Search Results
Your search for 3 matches 15628 pages
Showing 9851 - 9900FDA Accepts sBLA, Grants Priority Review for Obinutuzumab in Previously Untreated Follicular Lymphoma
On August 28, the U.S. Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for obinutuzumab (Gazyva) in combination with chemotherapy followed by obinutuzumab alone for patients with previously untreated follicular lymphoma....
2018 Pershing Square Sohn Cancer Research Prize Opens for Applications on October 2, 2017
The Pershing Square Sohn Cancer Research Alliance (PSSCRA) will begin accepting applications for its 2018 Pershing Square Sohn Prize for Young Investigators on October 2, 2017. At least six New York City area–based scientists will each be awarded $200,000 per year—for up...
Concurrent Treatment With OX40 Agonist Antibody and PD-1 Blockade
Although the potential for immunotherapy to improve outcomes for patients with cancer, particularly through a combination of agents targeting immune inhibitory pathways, is becoming increasingly evident, how to optimally combine the many new immunotherapy agents being developed remains a major...
Obinutuzumab vs Rituximab Plus CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma
The phase III GOYA trial has shown no progression-free survival advantage with obinutuzumab (Gazyva) vs rituximab (Rituxan) plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with advanced diffuse large B-cell lymphoma (DLBCL). The results were...
Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
As reported in the Journal of Oncology Practice by Chang et al, for the first time for any type of malignancy, the American Urological Association (AUA), ASCO, American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) have formulated an evidence-based guideline on...
Use of CD4-Positive T Cells With MHC Class II–Restricted Receptors Targeting MAGE-A3 in Metastatic Cancer
In a study reported in the Journal of Clinical Oncology, Lu et al found that autologous CD4-positive T cells engineered to express a major histocompatibility complex (MHC) class II–restricted T-cell receptor (TCR) targeting the cancer germline antigen MAGE-A3 (melanoma-associated antigen-A3)...
Reduced-Dose Cabazitaxel After Docetaxel in Metastatic Castration-Resistant Prostate Cancer
In the phase III PROSELICA trial reported by Eisenberger et al in the Journal of Clinical Oncology, a cabazitaxel (Jevtana) dose of 20 mg/m2 (C20) was noninferior for overall survival vs the currently recommended dose of 25 mg/m2 (C25) after docetaxel treatment in metastatic castration-resistant...
Prolonged and Intensified Neoadjuvant Therapy for Esophageal Adenocarcinoma
A UK phase III trial (UK MRC OE05) has shown no significant survival benefit of extended and intensified neoadjuvant chemotherapy with epirubicin, cisplatin, and capecitabine vs standard cisplatin/fluorouracil followed by resection in patients with esophageal adenocarcinoma. The findings were...
Anti–Trop-2 Antibody-Drug Conjugate Produces Durable Responses in Metastatic Triple-Negative Breast Cancer
AS REPORTED in the Journal of Clinical Oncology by Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center and Harvard Medical School, and colleagues, the anti–Trop-2 antibody-drug conjugate sacituzumab govitecan has been found to produce durable responses in patients with heavily...
AKT Inhibitor Ipatasertib in Metastatic Triple-Negative Breast Cancer
The randomized phase II LOTUS trial has shown improved progression-free survival with the addition of the AKT inhibitor ipatasertib to paclitaxel in the first-line treatment of metastatic triple-negative breast cancer. These results were reported by Kim et al in The Lancet Oncology. The PI3K/AKT...
Adjuvant Temozolomide in 1p/19q Non-Codeleted Anaplastic Glioma
Interim results of the phase III CATNON trial (EORTC study 26053-22054) indicate a survival benefit of adjuvant temozolomide in 1p/19q non-codeleted anaplastic glioma. These findings were reported in The Lancet by van den Bent et al. Study Details In the open-label 2 x 2 factorial trial, 745...
ASCO, CCF Congratulate 2017 Grant and Award Recipients
The Conquer Cancer Foundation of ASCO (CCF) presented more than $6.3 million in grants and awards to 247 promising oncology researchers at the 2017 ASCO Annual Meeting. CCF and ASCO congratulate the recipients on their contributions to the field of oncology and offer their profound thanks to the...
Detection of Early-Stage Cancers With Circulating Tumor DNA
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center, Baltimore, reported they have developed a test that spots tiny amounts of cancer-specific DNA in blood, and have used it to accurately identify more than half of 138 people with...
Adding First-Line Selective Internal Radiotherapy to Chemotherapy in Patients With Liver Metastases From Colorectal Cancer
A meta-analysis of three randomized trials (FOXFIRE, SIRFLOX, and FOXFIRE-Global) indicates no overall survival benefit of adding first-line selective internal radiotherapy to chemotherapy in patients with liver metastases from colorectal cancer. The findings were reported by Wasan et al in The...
Arsenic Trioxide and Reduced Anthracycline Dose in Pediatric Acute Promyelocytic Leukemia
In the phase III historically controlled Children’s Oncology Group (COG) AAML0631 trial, arsenic trioxide consolidation permitted the use of lower-dose anthracycline without appearing to compromise outcomes in pediatric patients with acute promyelocytic leukemia (APL). The results were...
Crizotinib in Pediatric ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors
In a Children’s Oncology Group study, high response rates were achieved with crizotinib (Xalkori) treatment in pediatric ALK-positive anaplastic large cell lymphomas (ALCL) and inflammatory myofibroblastic tumors. These results were reported by Mossé et al in the Journal of Clinical...
Off-the-Shelf, Virus-Specific T Cells for Treating Viral Infections After Transplantation
In a phase II study reported in the Journal of Clinical Oncology, Tzannou et al found that use of off-the-shelf, broad-coverage, adoptively transferred, virus-specific T cells was feasible and effective in treating viral infections in patients who had undergone allogeneic hematopoietic stem cell...
Brachytherapy for Prostate Cancer: An Old Form of Radiation Treatment That Is Still One of the Most Effective
BRACHYTHERAPY HAS a long track record in treating cancer, dating back to the first reported use of an implanted radioactive source in 1901, and brachytherapy for the treatment of prostate cancer dates back to 1914, when Pasteu and Degrais used a radium source inserted through a urethral catheter. ...
Pursuing Combination Strategies With Checkpoint and Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma
PRIMARY LIVER CANCER is the second leading cause of cancer-related death worldwide. Hepatocellular carcinoma accounts for 90% of liver cancer, with around 800,000 new cases diagnosed globally each year.1 In contrast to the stable or declining trends observed for most neoplasms, the incidence and...
CheckMate 040: Nivolumab Is Active in Advanced Hepatocellular Carcinoma
NIVOLUMAB (OPDIVO) has been found to produce durable responses in patients with advanced hepatocellular carcinoma in the phase I/II CheckMate 040 trial. These findings were reported in The Lancet by Anthony B. El-Khoueiry, MD, of USC Norris Comprehensive Cancer Center, and colleagues.1 Currently,...
International Consensus (or Not) on Management of Advanced Prostate Cancer
ALTHOUGH THE National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) strongly influence the management of advanced prostate cancer, they do not always reflect actual clinical practice. It turns out that in the real world, there are multiple areas ...
Cutting-Edge Induction Strategies and Novel Approach to Reducing Skeletal-Related Events Explored in Multiple Myeloma
THE ADDITION of daratumumab (Darzalex) to a triplet induction regimen led to good responses in newly diagnosed multiple myeloma, but not without toxicities. And in the treatment of myeloma bone disease, denosumab (Xgeva) in place of zoledronic acid preserved renal function and may be associated...
Deep Androgen Suppression Plus Abiraterone and Prednisone: Effective Strategy for Hormone-Naive Prostate Cancer
ANTAGONISM OF THE ANDROGEN AXIS remains a cornerstone of systemic therapy for high-risk localized and metastatic prostate cancer, reflecting the central role of androgen-dependent biologic mechanisms in hormone-naive disease. Despite the use of standard androgen-deprivation therapy, men with...
Updates of Key Trials in Metastatic Non–Small Cell Lung Cancer: KEYNOTE-024 and AvaALL
IMMUNOTHERAPY AND ANTIANGIOGENESIS were highlighted in a session on metastatic non–small cell lung cancer (NSCLC) at the Best of ASCO New Orleans meeting. Matthew Gubens, MD, MS, presented the selected abstracts from the ASCO Annual Meeting.1 Dr. Gubens is Associate Professor of Thoracic Medical...
Fighting Misinformation in HPV-Related Cancer Prevention
FAKE NEWS, junk science, and alternative facts seem pervasive in our current culture, to the detriment of important, verified scientific advancements. One area where this is quite evident is the vaccine against human papillomavirus (HPV). Although we have had a safe, effective vaccine since 2006...
Dabrafenib Plus Trametinib in BRAF V600–Mutant Melanoma Brain Metastases
A phase II trial has shown that the combination of the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinst) produces responses in brain metastases in patients with BRAF V600–mutant melanoma. These findings were reported by Michael A. Davies, MD, of The University of...
PD-L1 Expression and Radiation Resistance in Head and Neck Squamous Cell Carcinoma
According to a study by Heath D. Skinner, MD, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues, the primary cause of death in patients with head and neck squamous cell carcinoma is local treatment failure. Although human papillomavirus (HPV)-positive head and neck squamous ...
Look for Opportunities to Lower Barriers to Participation of Older Patients in Oncology Clinical Trials
Practicing evidence-based medicine requires evidence, but the evidence for efficacy and safety of new and evolving cancer therapies in older adults is wanting due to their underrepresentation in oncology clinical trials. “It is difficult to practice evidence-based medicine in an older population...
‘Slow, Incremental Changes’ Are Increasing Participation of Older Adults in Clinical Trials
Older adults continue to be proportionally underrepresented in oncology clinical trials, but the participation rate of adults aged 65 and older is increasing by “slow, incremental changes,” Stuart M. Lichtman, MD, FACP, FASCO, noted in an interview with The ASCO Post. Prompting those changes are...
CheckMate-214: Nivolumab and Ipilimumab in Intermediate- and Poor-Risk Previously Untreated Advanced or Metastatic RCC
On August 15, Bristol-Myers Squibb Company announced topline results from the CheckMate-214 trial investigating nivolumab (Opdivo) in combination with ipilimumab (Yervoy) vs sunitinib (Sutent) in intermediate- and poor-risk patients with previously untreated advanced or metastatic renal cell...
Recent FDA Actions Include New Drug Approvals in Leukemia, Expanded Approvals in Colorectal Cancer and Graft-vs-Host Disease
The U.S. Food and Drug Administration (FDA) recently granted approval, expanded approval, and breakthrough therapy designation to numerous treatments across a range of tumor types and malignancies. New Drug Approvals Daunorubicin-Cytarabine Combination (Vyxeos): On August 3, the FDA granted...
On My Way to Hospice Care, Immunotherapy Saved My Life
Two years ago, I was on my way to hospice care after numerous treatments, including surgery, chemotherapy, and radiation therapy failed to stop the progression of my stage IV castration-resistant prostate cancer. A last-minute call from my oncologist about a phase I combination trial of the...
End-of-Life Care for Older Patients With Acute Myeloid Leukemia
As reported in the Journal of Clinical Oncology by Wang et al, many older patients with acute myeloid leukemia (AML) do not receive hospice care at the end of life, with those who do tending to enroll in hospice within days of death. Study Details The population-based retrospective cohort study...
Plasma Epstein-Barr Virus DNA Screening for Nasopharyngeal Cancer
In a Hong Kong study reported in The New England Journal of Medicine, Chan et al found that screening for circulating cell-free Epstein-Barr virus (EBV) DNA is useful in detecting nasopharyngeal carcinoma in asymptomatic individuals. Study Details In the study, 20,174 participants underwent...
Turmeric
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, present information on...
Clinical Trials Actively Recruiting Patients With Stage II/III Colorectal Cancer
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on patients with stage II or III colorectal cancer. These studies highlight dietary intervention, supplements, immunotherapy, combination chemotherapy, neoadjuvant therapy, and...
Triple-Negative Breast Cancer: Practical Approach, Promising Research
Triple-negative breast cancer has a reputation for being a particularly challenging malignancy, but breast cancer specialist Nancy Davidson, MD, Senior Vice President of the Clinical Research Division at the Fred Hutchinson Cancer Research Center, Seattle, put this in perspective in a recent...
Germline Mutations in Apparent Sporadic Pancreatic Adenocarcinoma
As reported by Shindo et al in the Journal of Clinical Oncology, deleterious germline mutations in known pancreatic cancer susceptibility genes were frequently found in patients with pancreatic cancer who do not have a reported family history of cancer. Study Details The study involved sequencing ...
Effect of Azithromycin on Airflow Decline–Free Survival After Allogeneic HSCT for Hematologic Malignancy
The French phase III ALLOZITHRO trial, stopped early due to excessive hematologic relapse in the azithromycin group, showed worse airflow decline–free survival with azithromycin vs placebo after hematopoietic stem cell transplantation (HSCT) for hematologic malignancy. The study findings were ...
Colorectal Cancer Mortality Rates in Adults Aged 20 to 54 Years From 1970 to 2014
In a research letter to JAMA, Siegel et al reported that overall colorectal cancer mortality rates have declined in the United States between 1970 and 2014 in patients aged 20 to 54 years but increased in white persons in this age group between 2004 and 2014. Study Details In the study,...
Partial-Breast and Reduced-Dose Radiotherapy After Breast-Conserving Surgery
The UK IMPORT LOW phase III trial has shown noninferiority in local relapse for partial-breast and reduced-dose vs standard whole-breast radiotherapy after breast-conserving surgery in early breast cancer. These study results were reported by Coles et al in The Lancet. Study Details In the...
Clonal Hematopoiesis in Patients With Nonhematologic Cancers
In a study of nearly 9,000 people treated for solid tumors, researchers found that radiation treatment and tobacco use were linked to higher rates of blood-based DNA mutations that could lead to a higher risk for blood cancers such as leukemia. The study, published by Coombs et al in...
First-Line Cabazitaxel vs Docetaxel in Metastatic Castration-Resistant Prostate Cancer
The phase III FIRSTANA trial has shown no difference in overall survival with two dose regimens of cabazitaxel (Jevtana) vs docetaxel in the first-line treatment of metastatic castration-resistant prostate cancer. Results were reported by Oudard et al in the Journal of Clinical Oncology....
Final Overall Survival Results of GOG 240 Trial Adding Bevacizumab to Chemotherapy in Advanced Cervical Cancer
As reported in The Lancet by Tewari et al, the final overall survival results of the phase III Gynecologic Oncology Group (GOG) 240 trial show continued benefit of the addition of bevacizumab (Avastin) to chemotherapy in patients with metastatic, persistent, or recurrent cervical carcinoma. Study...
Health-Related Quality of Life With Immediate vs Delayed ADT in Prostate Cancer
In a health-related quality-of-life study among patients in the phase III TOAD trial, immediate vs delayed androgen-deprivation therapy was associated with early worsening of androgen-deprivation therapy–related symptoms but few other comparative adverse effects on functioning or quality of...
Senate Passes the RACE for Children Act
On August 3, the leadership of Kids v Cancer, an advocacy group promoting pediatric cancer research, issued the following statement: Today, the U.S. Senate passed the FDA Reauthorization Act and with it, the RACE for Children Act. Now, new cancer drugs will be developed not only for...
Ovarian Function Recovery During Anastrozole Therapy in Postmenopausal Patients With Breast Cancer
In the phase III DATA trial reported in the Journal of the National Cancer Institute by van Hellemond et al, 12% of women with breast cancer who had chemotherapy-induced ovarian function failure experienced ovarian function recovery during 30 months of aromatase inhibitor therapy with anastrozole....
Perioperative Anti-inflammatory, Antistress Drugs May Reduce Postsurgical Metastatic Disease Recurrence
Most cancer-related deaths are the result of postsurgical metastatic recurrence. A new Tel Aviv University (TAU) study published by Shaashua et al in Clinical Cancer Research found a specific drug regimen administered prior to and after surgery significantly reduces the risk of postsurgical cancer...
Lenalidomide Maintenance After Autologous Stem Cell Transplantation in Multiple Myeloma
According to a meta-analysis reported in the Journal of Clinical Oncology by McCarthy et al, lenalidomide (Revlimid) maintenance therapy after autologous stem cell transplantation (ASCT) was associated with improved progression-free and overall survival vs placebo or observation in patients with...
Nivolumab in Advanced DNA Mismatch Repair–Deficient or Microsatellite Instability–High Colorectal Cancer
The phase II CheckMate 142 trial has shown that nivolumab (Opdivo) produces durable responses in recurrent or metastatic DNA mismatch repair–deficient (dMMR)/microsatellite instability–high (MSI-H) colorectal cancer. These study findings were reported in The Lancet Oncology by Overman...
